Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients

Early hepatocellular carcinoma (HCC) diagnosis is challenging. Moreover, for patients with alpha-fetoprotein (AFP)-negative HCC, this challenge is augmented. MicroRNAs (miRs) profiles may serve as potential HCC molecular markers. We aimed to assess plasma homo sapiens—(hsa)-miR-21-5p, hsa-miR-155-5p, hsa-miR-192-5p, and hsa-miR-199a-5p—expression levels as a panel of biomarkers for HCC in chronic hepatitis C virus (CHCV) patients with liver cirrhosis (LC), especially AFP-negative HCC cases, as a step toward non-protein coding (nc) RNA precision medicine. Subjects and methods: 79 patients enrolled with CHCV infection with LC, subclassified into an LC group without HCC (n = 40) and LC with HCC (n = 39). Real-time quantitative PCR was used to measure plasma hsa-miR-21-5p, hsa-miR-155-5p, hsa-miR-192-5p, and hsa-miR-199a-5p. Results: Plasma hsa-miR-21-5p and hsa-miR-155-5p demonstrated significant upregulation, while hsa-miR-199a-5p demonstrated significant downregulation in the HCC group (n = 39) when compared to the LC group (n = 40). hsa-miR-21-5p expression was positively correlated with serum AFP, insulin, and insulin resistance (r = 0.5, p < 0.001, r = 0.334, p = 0.01, and r = 0.303, p = 0.02, respectively). According to the ROC curves, for differentiating HCC from LC, combining AFP with each of hsa-miR-21-5p, hsa-miR-155-5p, and miR199a-5p improved the diagnostic sensitivity to 87%, 82%, and 84%, respectively, vs. 69% for AFP alone, with acceptable specificities of 77.5%, 77.5%, and 80%, respectively, and AUC = 0.89, 0.85, and 0.90, respectively vs. 0.85 for AFP alone. hsa-miR-21-5p/hsa-miR-199a-5p and hsa-miR-155-5p/hsa-miR-199a-5p ratios discriminated HCC from LC at AUC = 0.76 and 0.71, respectively, with sensitivities = 94% and 92% and specificities = 48% and 53%, respectively. Upregulation of plasma hsa-miR-21-5p was considered as an independent risk factor for HCC development [OR = 1.198(1.063–1.329), p = 0.002]. Conclusions: Combining each of hsa-miR-21-5p, hsa-miR-155-5p, and hsa-miR-199a-5p with AFP made it possible to identify HCC development in the LC patients’ cohort with higher sensitivity than using AFP alone. hsa-miR-21-5p/hsa-miR-199a-5p and hsa-miR-155-5p/hsa-miR-199a-5p ratios are potential HCC molecular markers for AFP-negative HCC patients. hsa-miR-21-5p was linked, clinically and via in silico proof, to insulin metabolism, inflammation, dyslipidemia, and tumorigenesis in the HCC patients’ group as well as for an upregulated independent risk factor for the emergence of HCC from LC in the CHCV patients.

[1]  M. Kanehisa,et al.  KEGG for taxonomy-based analysis of pathways and genomes , 2022, Nucleic Acids Res..

[2]  N. Hamdy,et al.  Cytotoxic T Cell Expression of Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) in Viral Hepatitis C-Mediated Hepatocellular Carcinoma , 2022, International journal of molecular sciences.

[3]  M. Klammer,et al.  Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma , 2022, World journal of gastroenterology.

[4]  E. Badr,et al.  MicroRNA-29a and MicroRNA-124 as novel biomarkers for hepatocellular Carcinoma. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[5]  C. Zhong,et al.  JPHYD Inhibits miR-21-5p/Smad7-Mediated Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells , 2022, Journal of oncology.

[6]  Xubin Li,et al.  A Predictive Nomogram of Early Recurrence for Patients with AFP-Negative Hepatocellular Carcinoma Underwent Curative Resection , 2022, Diagnostics.

[7]  E. Børsheim,et al.  Circulating microRNAs Are Associated With Metabolic Markers in Adolescents With Hepatosteatosis , 2022, Frontiers in Endocrinology.

[8]  Haiyang Yu,et al.  Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment , 2022, Journal of Hematology & Oncology.

[9]  Tong Li,et al.  A novel prognostic model for hepatocellular carcinoma based on 5 microRNAs related to vascular invasion , 2022, BMC Medical Genomics.

[10]  Shinya Takahashi,et al.  Current treatment strategies and future perspectives for gastrointestinal stromal tumors , 2022, World journal of gastrointestinal pathophysiology.

[11]  N. Hamdy,et al.  Competitive Endogenous Role of the LINC00511/miR-185-3p Axis and miR-301a-3p From Liquid Biopsy as Molecular Markers for Breast Cancer Diagnosis , 2021, Frontiers in Oncology.

[12]  Song He,et al.  Investigation of Potential Molecular Biomarkers for Diagnosis and Prognosis of AFP-Negative HCC , 2021, International journal of general medicine.

[13]  N. Hamdy,et al.  MicroRNAs’ role in the environment-related non-communicable diseases and link to multidrug resistance, regulation, or alteration , 2021, Environmental Science and Pollution Research.

[14]  A. Lohse,et al.  Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients , 2021, Cancers.

[15]  Dan Guo,et al.  In vitro and in vivo anti-metastatic effect of the alkaliod matrine from Sophora flavecens on hepatocellular carcinoma and its mechanisms. , 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[16]  Kyoung-Jin Oh,et al.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC , 2021, International journal of molecular sciences.

[17]  Pengcheng Zhou,et al.  LncRNA XIST upregulates TRIM25 via negatively regulating miR-192 in hepatitis B virus-related hepatocellular carcinoma , 2021, Molecular medicine.

[18]  M. Sobh,et al.  Role of exopolysaccharides (EPSs) as anti-Mir-155 in cancer cells , 2021, Heliyon.

[19]  D. Lancet,et al.  GeneCaRNA: a comprehensive gene-centric database of human non-coding RNAs in the GeneCards Suite. , 2021, Journal of molecular biology.

[20]  G. Her,et al.  RETRACTED: MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling , 2021, Cancers.

[21]  D. Ribatti,et al.  microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis , 2020, Frontiers in Oncology.

[22]  P. Malfertheiner,et al.  Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function , 2020, World journal of hepatology.

[23]  Jairo Navarro Gonzalez,et al.  The UCSC SARS-CoV-2 Genome Browser , 2020, Nature Genetics.

[24]  M. Ávila,et al.  Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg , 2020, JHEP reports : innovation in hepatology.

[25]  Min Lin,et al.  Emerging role of FBXO22 in carcinogenesis , 2020, Cell Death Discovery.

[26]  S. Dima,et al.  Plasma Small Extracellular Vesicles Derived miR-21-5p and miR-92a-3p as Potential Biomarkers for Hepatocellular Carcinoma Screening , 2020, Frontiers in Genetics.

[27]  A. Romano,et al.  Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma , 2020, Cancers.

[28]  N. Kawada,et al.  The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease , 2020, International journal of molecular sciences.

[29]  David Haussler,et al.  The UCSC SARS-CoV-2 Genome Browser , 2020, Nature Genetics.

[30]  R. Ahmed,et al.  MiR-155 and MiR-665 Role as Potential Non-invasive Biomarkers for Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection , 2020, Journal of translational internal medicine.

[31]  Xiaowei Wang,et al.  miRDB: an online database for prediction of functional microRNA targets , 2019, Nucleic Acids Res..

[32]  P. Xue,et al.  Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth , 2019, Molecular Cancer.

[33]  Andrea Tsoris,et al.  Use Of The Child Pugh Score In Liver Disease , 2019 .

[34]  J. Yun,et al.  Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis , 2019, Theranostics.

[35]  Xiaowei Wang,et al.  Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data , 2019, Genome Biology.

[36]  J. Tu,et al.  Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage , 2019, Pathology & Oncology Research.

[37]  Q. Zhan,et al.  miR-192-5p Silencing by Genetic Aberrations Is a Key Event in Hepatocellular Carcinomas with Cancer Stem Cell Features. , 2018, Cancer research.

[38]  Y. Takeda,et al.  Exosomal miR-155 Derived from Hepatocellular Carcinoma Cells Under Hypoxia Promotes Angiogenesis in Endothelial Cells , 2018, Digestive Diseases and Sciences.

[39]  M. Speicher,et al.  Current and future perspectives of liquid biopsies in genomics-driven oncology , 2018, Nature Reviews Genetics.

[40]  P. Sutphin,et al.  Staging systems of hepatocellular carcinoma: A review , 2018, Indian Journal of Gastroenterology.

[41]  Xiaoxia Zhou,et al.  Low expression of miR-199 in hepatocellular carcinoma contributes to tumor cell hyper-proliferation by negatively suppressing XBP1 , 2018, Oncology letters.

[42]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[43]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[44]  H. Cortez‐Pinto,et al.  miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice , 2017, Cell Death & Disease.

[45]  Sang Gyune Kim,et al.  Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma , 2017, Medicine.

[46]  H. Shan,et al.  MiR‐199a‐5p suppresses tumorigenesis by targeting clathrin heavy chain in hepatocellular carcinoma , 2017, Cell biochemistry and function.

[47]  K. Yoon,et al.  Triglycerides/glucose index is a useful surrogate marker of insulin resistance among adolescents , 2017, International Journal of Obesity.

[48]  Lili Liu,et al.  MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma , 2017, Oncotarget.

[49]  C. Tsao,et al.  Emerging role of microRNA-21 in cancer (Review) , 2016 .

[50]  F. He,et al.  The platelet-to-lymphocyte ratio, superior to the neutrophil-to-lymphocyte ratio, correlates with hepatitis C virus infection. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[51]  V. Paradis,et al.  Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression , 2015, Gut.

[52]  Artemis G. Hatzigeorgiou,et al.  DIANA-miRPath v3.0: deciphering microRNA function with experimental support , 2015, Nucleic Acids Res..

[53]  Sreeparna Banerjee,et al.  PPARG (peroxisome proliferator-activated receptor gamma) , 2011 .

[54]  Tsviya Olender,et al.  GeneDecks: paralog hunting and gene-set distillation with GeneCards annotation. , 2009, Omics : a journal of integrative biology.

[55]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[56]  威志 三光寺 顎関節軟骨線維層におけるEGF(Epidermal Growth Factor)の影響について , 1999 .

[57]  J. Flier,et al.  Insulin resistance--mechanisms, syndromes, and implications. , 1991, The New England journal of medicine.